Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN4 | O15554 | 6/20 | 0.45 |
| ▸ | PDE2A | O00408 | 8/20 | 0.39 |
| ▸ | RORC | P51449 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22470163 | 0.90 | KCNN4 (0.43) | KCNN4PDE2ARORCARHDAC3 | |
| SCHEMBL22470421 | 0.86 | KCNN4 (0.54) | KCNN4PDE2AARHDAC3HDAC1 | |
| SCHEMBL28649317 | 0.83 | KCNN4 (0.53) | KCNN4PDE2AHDAC3HDAC1HDAC2 | |
| SCHEMBL22470246 | 0.82 | KCNN4 (0.40) | KCNN4PDE2AHDAC3HDAC1HDAC2 | |
| SCHEMBL28645012 | 0.81 | KCNN4 (0.51) | KCNN4PDE2AARHDAC3HDAC1 | |
| SCHEMBL22470405 | 0.80 | KCNN4 (0.47) | KCNN4PDE2AHDAC3HDAC1HDAC2 | |
| SCHEMBL31658191 | 0.79 | KCNN4 (0.46) | KCNN4PDE2AHDAC3HDAC1HDAC2 | |
| SCHEMBL22470175 | 0.79 | KCNN4 (0.46) | KCNN4PDE2AHDAC3HDAC1HDAC2 | |
| SCHEMBL22470411 | 0.78 | KCNN4 (0.45) | KCNN4PDE2AHDAC3HDAC1HDAC2 | |
| SCHEMBL22470323 | 0.78 | KCNN4 (0.43) | KCNN4PDE2ARORCHDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220169602-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | SANIONA A/S (DK) | 2022-06-02 | — | — | US | claimed |
| EP-3941903-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | Saniona A/S (DK) | 2022-01-26 | — | — | EP | claimed |
| WO-2020193419-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | SANIONA A/S (DK) | 2020-10-01 | — | — | WO | claimed |
| US-12006289-B2 | Potassium channel inhibitors | SANIONA A/S (DK) | 2024-06-11 | — | — | US | disclosed |
| US-20220169602-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | SANIONA A/S (DK) | 2022-06-02 | — | — | US | disclosed |
| EP-3941903-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | Saniona A/S (DK) | 2022-01-26 | — | — | EP | disclosed |
| WO-2020193419-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | SANIONA A/S (DK) | 2020-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220169602-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | KCNN2, KCNJ2, KCNN1 | KCNN4 57/4885PDE2A 730/4885RORC 2964/4885 |
| US-12006289-B2 | Potassium channel inhibitors | KCNJ2, KCNN2, KCNN1 | KCNN4 48/4885PDE2A 999/4885RORC 2789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.